Ikarian Capital, LLC Seres Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $1.43 Million - $2.95 Million	-409,314 Reduced 75.71%	131,310 $843,000
Q2 2022 Aug 12, 2022	SELL	$2.7 - $7.62 $810,000 - $2.29 Million	-300,000 Reduced 35.69%	540,624 $1.85 Million
Q1 2022 May 13, 2022	BUY	$6.3 - $8.84 $281,742 - $395,333	44,721 Added 5.62%	840,624 $5.99 Million
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $1.14 Million - $2.16 Million	189,349 Added 31.22%	795,903 $6.63 Million
Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $1.4 Million - $5.8 Million	256,554 Added 73.3%	606,554 $4.22 Million
Q1 2021 May 17, 2021	BUY	$17.66 - $28.92 $4.5 Million - $7.36 Million	254,570 Added 266.76%	350,000 $7.21 Million
Q3 2020 Nov 16, 2020	BUY	$3.74 - $28.74 $356,908 - $2.74 Million	95,430 New	95,430 $2.7 Million

46.7M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $102M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.